http://www.oxford-instruments.com/Pages/home.aspx


Oxford Instruments is a leading provider of high technology tools and systems for research and industry. We design and manufacture equipment that can fabricate, analyse and manipulate matter at the atomic and molecular level.

Oxford Instruments has discrete business groups operating in three sectors. This means we can focus our expertise, our technologies and our innovation on offering our customers high quality products and service that meet their stringent requirements.







Financial Calendar


Half Year/Interim Results Announcement

Tuesday November 13th 2012 : 9.30am The London Stock Exchange

Annual General Meeting:

Tuesday 11th September 2012 : 2.30pm

Oxford Instruments plc, Tubney Woods, Abingdon, Oxon OX13 4QX

26 September 2012 Ordinary shares quoted ex-dividend
28 September 2012 Record date for final dividend
30 September 2012 DRIP date
25 October 2012 Payment of final dividend
March 2013 Ordinary shares quoted ex-dividend
Dividend reinvestment (DRIP) last date for election
Record date for interim dividend
31 March 2013 Financial Year End

Shares - We see scope to surprise on the upside as conditions improve into 2015.

13 Oct Investec 1,405.00 Buy

Interim results Tues 11 Nov

Half Yearly Report

RNS


RNS Number : 6598W

Oxford Instruments PLC

11 November 2014






Release Date: 7am Tuesday 11th November 2014



Oxford Instruments plc

Announcement of Half Year Results for 2014/2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Half Year Results for the six months to 30 September 2014.



Highlights:



· First half orders up 19.9% to £201.5 million (2013: £168.0 million); on a constant currency organic basis, orders up 7.4%.

· First half revenue up 7.3% to £178.5 million (2013: £166.3 million); on a constant currency organic basis revenues down 5.9%.

· Adjusted operating profit* of £18.9 million (2013: £22.0 million).

· Adjusted EPS of 20.9 pence (2013: 28.6 pence).

· Andor Technology acquisition integrating well and performing ahead of expectations; integration of RMG and RoentgenAnalytik acquisitions also proceeding to plan.

· Investment in R&D up 41% to £18.3 million with sustained momentum in new product introductions and strong new product pipeline.

· Interim dividend increased by 10.1% to 3.7 pence per share (2013: 3.36 pence).

*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in Note 2.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said "We will continue to focus on developing innovative new products and growing market share in our core areas of physical science. Our strategy will extend our reach into adjacent new markets by applying our tools and technologies to life science research and analysis, thus extending the reach and reputation of the Oxford Instruments brand worldwide."

----------------------------------------------------------------------------------------------

11 Nov Investec N/A Under Review
11 Nov Numis 1,350.00 Add
11 Nov N+1 Singer 1,350.00 Hold

Trading Statement
RNS
RNS Number : 8176C
Oxford Instruments PLC
22 January 2015



Release date: 7am 22nd January 2015

Oxford Instruments plc Quarter 3 Trading Update

22 January 2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues a Quarter 3 Trading Update which covers the period from 1st October 2014 to date.



In the third quarter organic orders and revenues were similar to the same period last year. In addition, Andor the acquisition made in the fourth quarter last year continues to perform well.



Significant orders, both taken in the year and forecast to be taken in Quarter 4, are for delivery to Russia. Recent tightening in the application of trade sanctions and, in particular the cancelling of certain export licences mean we no longer expect to convert theses orders to sales. We now assume that no sales can be made to Russia for the remainder of this year and we are also assuming no sales to Russia next year.



In addition, our forecast of recovery in the Japanese market has not yet occurred. The effects of Russia and Japan, combined with weaker trading in our short lead-time Industrial Analysis business means that, whilst we expect revenues for the second half to be ahead of the same period last year, we believe they will fall short of market expectations. We now anticipate adjusted profit before tax for the current year will be approximately £35 million.



In response to these challenges we are taking action to reduce costs and improve efficiency. Subject to consultation this may result in the closure of some sites and a reduction in headcount. This project aims to produce a cost saving of £6 million in the next financial year. The one off, cash costs of achieving these savings are expected to be in the region of £5 million which will be taken as an exceptional item in the current year.



Whilst it is not possible to predict when the situation in Russia will recover, order intake in Japan is improving. We expect to see the Group grow next year and beyond as we execute on our nanotechnology strategy.

Oxford Instruments (OXIG), down 27.95p, said in response to challenges in Russia and Japan it is taking action to reduce costs and improve efficiency, which could result in some site closures and reduction in headcount. It saw adjusted FY pretax profit at about £35m.

What a slapping!

2 Mar JP Morgan... 1,200.00 Overweight
2 Mar N+1 Singer 765.00 Hold

Acquisition
RNS
RNS Number : 9497L
Oxford Instruments PLC
01 May 2015





Release date: 1 May 2015



Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).



Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").



The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.



MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:



· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.



Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.



In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).







Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:



Dial: +44 (0)20 3139 4830

PIN: 89662683#







- Ends -

5 May Numis 1,150.00 Buy
5 May Beaufort... N/A Buy
5 May Jefferies... 990.00 Hold
5 May JP Morgan... 1,200.00 Overweight

29 May JP Morgan... 1,200.00 Overweight

Oxford Instruments, a leading provider of high technology tools and systems for industry and research, will announce its results for the year ended 31 March on 9 June.

JV for Oxford Instruments' Omicron business
RNS
RNS Number : 4609O
Oxford Instruments PLC
28 May 2015



For immediate release: 28 May 2015



Oxford Instruments plc

Oxford Instruments enters into Joint Venture with GD Intressenter AB, comprising Omicron Nanotechnology and Scienta Scientific



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces that it has entered into a Joint Venture with GD Intressenter AB of Sweden ("GDI") to create the world's largest player in the highly specialised Ultra High Vacuum Surface Science field. The JV will comprise Oxford Instruments' Omicron Nanotechnology GmbH and associated subsidiaries ("Omicron") and GDI's Scienta Scientific AB and associated subsidiaries ("Scienta").

In consideration for new shares in Scienta, Oxford Instruments has transferred all of its shares in the capital of Omicron to Scienta. Oxford Instruments holds a 47 per cent interest in the share capital of Scienta and GDI holds 53 per cent.

The JV provides excellent opportunities to enhance product development, cut production costs and broaden the product range, while extending market reach and strengthening customer relationships.

The Board of Directors of the JV will include representatives from GDI and Oxford Instruments. The CEO of the new business will be Mr Johan Åman who is based in Uppsala, Sweden. Mr Åman has been CEO of Scienta since 2013 and prior to this he held senior commercial and research positions in Mycronic AB. GDI is backed by a leading Nordic Venture Capital Firm, InnovationsKapital, and other financial investors.



In the twelve months to 31st March 2014, Omicron generated revenue of £28.5 million and a loss before tax of £0.6 million. The gross assets of Omicron at 30th September 2014 were £26.1 million. In the financial year to 31st December 2014, Scienta generated revenue of SEK279 million (approximately £24.6 million) and a profit before tax of SEK25 million (approximately £2.2 million). The gross assets of Scienta at 31st December 2014 were SEK146 million (approximately £12.9 million). Oxford Instruments has provided a term loan of SEK40 million (approximately £3.1 million) to the JV. The transaction will result in no profit or loss on the carrying value of Omicron for Oxford Instruments.



Commenting on the establishment of the JV, Jonathan Flint, Chief Executive of Oxford Instruments, stated:



"This new venture will create the largest player in the exciting field of Surface Science and UHV engineering. Customers will benefit from an enhanced product portfolio and improved service, and the synergies generated by merging the two businesses will provide significant efficiencies and cost savings."



Lars Hagdahl, Chairman of GDI and of the JV, said:

"I am very pleased with the creation of this JV. Going forward together we are a larger and stronger business that will be good for our customers, partners and employees."

Final Results

Watch: Oxford Instruments - Results for the year to 31 March 2015

click here

Lost contact with this but it does move about a bit.

In a downward way, yes. :-))

(ShareCast News) - Oxford Instruments shares should be sold, said the Sunday Times' Inside the City column. The high-tech device maker spun out of Oxford University in 1959 needs to operate right on the bleeding edge of technology, and often depends on acquisitions to stay relevant - but not even that strategy is guaranteed to deliver reliable profits. The company has suffered two profit warnings in the last year, blamed on the sanctions on Russia and China's economic slowdown.
Although OxInst is trading at an attractive discount to rivals on a price-to-earnings basis, the balance sheet is a worry. With the squeeze being felt from weak Japanese demand, slowing industrial sales and lower prices for superconductor parts, management cut 7% of staff last year and recently negotiated better credit terms from lenders. Broker Jefferies has warned that the company's leverage ratios could get close to the higher level its banks have allowed, which any worsening of the Chinese economy, for example, will land OxInst in big trouble.

Market Buzz

Oxford Instruments slumps on Goldman downgrade

Mon, 19 October 2015

Oxford Instruments Quote more



Price: 596.00

Chg: -67.00

Chg %: -10.11%

Date: 17:00



(ShareCast News) - Shares in Oxford Instruments fell sharply after Goldman Sachs downgraded the stock to 'neutral' from 'buy', noting it's trading close to the bank's unchanged 700p price target.
The brokerage said that since being added to the 'buy' list on 26 September 2012, the stock is down 49.4%, compared to the FTSE World Europe up 19.9%.

For full-year 2016, Goldman said it expects adjusted earnings before interest and tax of £43m, compared to Reuters consensus of £45m.

"Weak demand in both the nanotech tools and industrial products business have impacted the shares, and more recently signs of price pressure related to overcapacity in superconducting wire," it said.

Goldman said the group has developed a strong portfolio in the area of nanotech tools. This is a niche market and while it is vulnerable to high short-term volatility, it could offer attractive long-term growth potential and/or strategic attractions for larger instrumentation suppliers, it added.

At 1013 BST, shares in Oxford Instruments were down 8.4% at 607.48p.

Group Financial Director steps down. http://www.moneyam.com/action/news/showArticle?id=5139917

SP down 4% so far.

A Disposal http://www.moneyam.com/action/news/showArticle?id=5159396